Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P27797

UPID:
CALR_HUMAN

ALTERNATIVE NAMES:
CRP55; Calregulin; Endoplasmic reticulum resident protein 60; HACBP; grp60

ALTERNATIVE UPACC:
P27797; Q6IAT4; Q9UDG2

BACKGROUND:
Calreticulin, also referred to as Endoplasmic reticulum resident protein 60 and HACBP, is integral to the calreticulin/calnexin cycle, ensuring proper protein folding and quality control in the ER. Its ability to interact with NR3C1 and influence nuclear export, alongside its participation in calcium homeostasis and oocyte maturation, underscores its multifaceted role in cellular physiology.

THERAPEUTIC SIGNIFICANCE:
The exploration of Calreticulin's functions offers a promising avenue for the development of novel therapeutic interventions. Given its central role in protein folding and calcium regulation, targeting Calreticulin could lead to breakthroughs in treating conditions stemming from protein misfolding and calcium imbalances.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.